The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies
Maryam Shafaati,
Kowsar Bagherzadeh,
Majid Lotfinia,
Hesam Karimi,
Ali Teimoori,
Mehdi Razazian,
Sepideh Meidaninikjeh,
Hamed Hosseini,
Hamid Reza Jamshidi,
Hasan Jalili,
Asghar Abdoli
Affiliations
Maryam Shafaati
Department of Microbiology, Faculty Science, Jahrom Branch, Islamic Azad University, Jahrom, Iran
Kowsar Bagherzadeh
Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran; Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran
Majid Lotfinia
Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
Hesam Karimi
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Ali Teimoori
Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Mehdi Razazian
Universite Paris Saclay, INSERM U1193, AP-HP, Hôpital Paul Brousse, Virology Department, France; Institute for Physiology and Pathophysiology, Johannes Kepler University Linz, Altenberger Strasse 69, 4040, Linz, Austria
Sepideh Meidaninikjeh
Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran
Hamed Hosseini
Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
Hamid Reza Jamshidi
Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Hasan Jalili
Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
Asghar Abdoli
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran; Corresponding author. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.,
Over time, the antigenic evolution of emerging variants of SARS-CoV-2 has demanded the development of potential protective vaccines. Administration of additional doses of current vaccines based on the WT spike protein may boost immunity, but their effectiveness has dwindled for patients with more recent variants. Here, we studied the neutralization activity of post-WT strain-based vaccination and a structural simulation in-silico based on the interactions of the RBD-hACE2 as the key to initiating infection among the VOCs of SARS-CoV-2. Our data display shows that WT sera showed a markedly greater reduction in Delta and Omicron, suggesting that the Wuhan-based vaccines may be more susceptible to breakthrough and new VOCs. According to the MD simulation, mutations of Omicron result in a significant change in the variant charge distribution throughout the binding interface that consequently alters the critical interface electrostatic potential in comparison to other variants. This observation provides new insights into immunization policy and next-generation vaccine development.